Preview

Медицинский алфавит

Расширенный поиск

Хроническая спонтанная крапивница: новости о проблеме и лечении (обзор литературы)

https://doi.org/10.33667/2078-5631-2019-2-26(401)-15-20

Полный текст:

Аннотация

Несмотря на достижения в понимании механизмов развития хронической крапивницы, в большом проценте случаев отмечаются неудовлетворенные результаты лечения, отсутствует возможность контроля заболевания. В настоящее время терапия пациентов с хронической крапивницей носит этапный характер. В 2014 году в России зарегистрирован по расширенным показаниям препарат омализумаб, дающий возможность достижения контроля при рефрактерной форме хронической спонтанной (идиопатической) крапивницы. В статье представлены данные об эффективности и безопасности его применения. По результатам многочисленных исследований омализумаб продемонстрировал быстрый и выраженный эффект при лечении пациентов с хронической спонтанной крапивницей, не отвечающих на терапию блокаторами Н1-гистаминовых рецепторов. Рассмотрены вопросы эффективной дозы, безопасности и переносимости терапии, сроков оценки эффективности, длительности курса и тактик ведения пациентов при частичном ответе или отсутствии ответа.

Об авторе

Л. С. Круглова
ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента России
Россия

д. м. н., проф., проректор по учебной работе, зав. кафедрой, кафедра дерматовенерологии и косметологии

г. Москва



Список литературы

1. Zuberbier T, Aberer W, Asero R/ et al. The EAACI/ GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018 Jul; 73 (7): 1393–1414.

2. Maurer M., Weller K., Bindslev-Jensen C. et al. Unmet clinical needs in chronic spontaneous urticaria. GA-2LEN task forse report. Allergy. 2011, v. 66, p. 317–330.

3. Bernstein J. A. et al. The diagnosis and management of acute and chronic urticaria: 2014 update // Journal of Allergy and Clinical Immunology. — 2014. — Т. 133. — No. 5. — С. 1270–1277.

4. Ruggeri RM, Imbesi S, Saitta S, et al. Chronic idiopathic urticaria and Graves’ disease. J Endocrinol Invest 2013; 36: 531–6.

5. Legrain V., Taieb A, Sage T, et al. Epidemiology of urticaria in infants. Allerg Immunol 1993; 25 (8): 324–326.

6. Asero R, Pinter E, Marra AM, et all. Current challenges and controversies in the management of chronic spontaneous urticaria. Expert Rev Clin Immunol 2015; 11: 1073–82.

7. Silvares MRC, Fortes MR, Miot HA. et al. CSU and Angioedema. Rev Assoc Med Bras 2011; 57: 577–82.

8. O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197–201.

9. Bracken, Sonali, Soman Abraham, and Amanda S. MacLeod. Autoimmune Theories of Chronic Spontaneous Urticaria. Frontiers in Immunology 10 (2019): 627.

10. Kolkhir P. Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know // Journal of Allergy and Clinical Immunology. — 2017. — Т. 139. — No. v6. — С. 1772–1781.

11. Church M, Kolkhir P, Metz M, et al. The role and relevance of mast cells in urticaria // Immunological reviews. — 2018. — Т. 282. — No. 1. — С. 232–247.

12. Altrichter S, Peter HJ, Pisarevskaja D, et al. IgE mediated autoallergy against thyroid peroxidase — a novel pathomechanism of chronic spontaneous urticaria? PLoS One 2011; 6: e14794.

13. Schmetzer O. Lakin E, Topal FA, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria // Journal of Allergy and Clinical Immunology. — 2018. — Т. 142. — No. 3. — С. 876–882.

14. Bossi F., Frossi B., Radillo O. et al. Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation // Allergy. 2011, Sep 12. Epub ahead of print.

15. Cugno M., Marzano A. V., Asero R., et al. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications // Intern. Emerg. Med. 2009; 5 (2): 97–101.

16. Zuberbier T, Asero R, Bindslev-Jensen C, et al. Position paper EAACI/GA2LEN/EDF/WAO guideline: definition, classificationand diagnosis of urticaria, Allergy 2009: 64: 1417–1426.

17. Колхир П. В. Крапивница и ангиоотек. Практическая медицина. М, 2012. 363–65.

18. Kulthanan K, Jiamton S, Thumpimukvatana N, et al. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007; 34: 294–301.

19. Клинические рекомендации по лечению больных крапивницей. — РОДВК. — 2016. — 31 с.

20. Guillén-Aguinaga S. Jáuregui Presa I, Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis // British Journal of Dermatology. — 2016. — Т. 175. — No. 6. — С. 1153–1165.

21. Makris M., Maurer M., Zuberbier T. Pharmacotherapy of chronic spontaneous urticaria. Expert Opin. Pharmacother. 2013, v. 14, p. 2511–2519.

22. Ledford D, Broder MS, Antonova E, et al. Corticosteroid-related toxicity in patients with chronic idiopathic urticaria-chronic spontaneous urticaria // Allergy and asthma proceedings. — OceanSide Publications, Inc, 2016. — Т. 37. — No. 6. — С. 458–465.

23. US Food and Drug Administration. Xolair1; 1 (omalizumab) for injection, for subcutaneous use. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/103976s5161lbl.pdf.

24. European Medicines Agency. Xolair 75 mg powder and solvent for solution for injection. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf

25. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007; 99: 190–3.

26. Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol 2010; 90: 443–4.

27. Magerl M, Staubach P, Altrichter S, et al. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol 2010; 126: 665–6.

28. Silva PM, Costa AC, Mendes A, et al. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria. Allergol Immunopathol (Madr) 2015; 43: 168–73.

29. Viswanathan RK, Moss MH, Mathur SK. Retrospective analysis of the efficacy of omalizumab inchronic refractory urticaria. Allergy Asthma Proc 2013; 34: 446–52.

30. Armengot-Carbo M, Velasco-Pastor M, Rodrigo-Nicolas B, et al. Omalizumab in chronic urticaria: a retrospective series of 15 cases. Dermatol Ther 2013; 26: 257–9.

31. Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122: 569–73.

32. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128: 567–73.

33. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924–35.

34. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132: 101–9.

35. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/ spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015; 135: 925.

36. Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016; 137: 1742.e4–1750.e4.

37. Tharp M, Bernstein J.A, Kavati, et al. Benefits and Harms of Omalizumab Treatment in Adolescent and Adul tPatients With Chronic Idiopathic (Spontaneous) Urticaria A Meta-analysis of ‘Real-world’ Evidence. JAMA Dermatology. — 2019. — Vol. 155. — No. 1. — 29–38р.

38. Staubach P, Metz M, Chapman-Rothe N, et al. Omalizumab rapidly improves angioedemarelated quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy. 2017; 00: 1–9.

39. Asero R, Canonicab G, Cristaudoc A, et al. Critical appraisal of the unmet needs in the PINION treatment of chronic spontaneous urticaria with omalizumab: an Italian perspective. Wolters Kluwer Health –2017. — Vol. 17. — No. 6. — 453–459.

40. Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol 2016; 137: 474–481.

41. Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br J Dermatol 2016; 175: 404–406.

42. Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria. Ann Allergy Asthma Immunol 2015; 115: 126–129.

43. Metz M, Ohanyan T, Church MK, et al. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014; 150: 288–290. 42–46.

44. Vestergaard C, Toubi E, Maurer M, et al. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. Eur J Dermatol 2017; 27: 10–19.

45. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014; 133 (5): 1270–1277.

46. Инструкция по медицинскому применению препарата Ксолар ® : grls.rosminzdrav.ru (дата обращения 18.09.19).

47. Metz M. et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis // Journal of dermatological science. — 2014. — Т. 73. — No. 1. — С. 57–62.


Для цитирования:


Круглова Л.С. Хроническая спонтанная крапивница: новости о проблеме и лечении (обзор литературы). Медицинский алфавит. 2019;2(26):15-20. https://doi.org/10.33667/2078-5631-2019-2-26(401)-15-20

For citation:


Kruglova L.S. Chronic spontaneous urticaria: news about problem and treatment (literature review). Medical alphabet. 2019;2(26):15-20. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-26(401)-15-20

Просмотров: 405


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2078-5631 (Print)